Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pro-Pharmaceuticals
Newton, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Pro-Pharmaceuticals' lead asset, DAVANAT, a galactomannan polymer targeting galectin receptors, completed Phase II clinical trials for colorectal cancer adjunct therapy, intending to improve efficacy and safety of existing chemotherapies. No recent clinical results or commercial approvals available; the company has not announced progress since circa 2008 and appears defunct.
- Therapeutic areas
- GastroenterologyOncologyInfectious DiseasesImmunology
- Modalities
- Polymer-drug conjugate therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Pro-Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pro-Pharmaceuticals.